Injuries & Orthopedics
Peptides for Shoulder Injuries & Rotator Cuff Repair: Evidence
A clinical, evidence-first look at the peptides pitched for rotator-cuff tears, labral injury and shoulder tendinopathy — BPC-157, TB-500/thymosin β-4, and GHK-Cu — and why all three are graded C (preclinical only) for the shoulder.
Rotator cuffBPC-157TB-500GHK-CuPreclinical only
The quick verdict
The honest 2026 read: no human trial exists for any peptide in rotator-cuff, labral, or shoulder-tendon injury — BPC-157, TB-500/thymosin β-4 and GHK-Cu are all graded C (preclinical only) for the shoulder.
- Best overall
- BPC-157 — The only peptide with a shoulder-specific (rat rotator-cuff) study plus the deepest rodent tendon/enthesis dossier — but still zero human shoulder evidence, and that rat datapoint is a single unpublished abstract. 'Best' here means best-studied, not proven.
- Best value
- Physical therapy + load management (and PRP where indicated) — Not a peptide, but the honest value pick: structured PT, load management and surgical repair for appropriate tears carry the human evidence, and PRP is the one injectable with a real (if debated) human rotator-cuff base.
- Best for A tested athlete or military service member
- Neither peptide — BPC-157 is banned at all times by WADA (S0) and TB-500/thymosin β-4 as a growth factor (S2.3), with no TUE, and both are on the DoD prohibited list — use is a violation regardless of intent.
How we evaluated
We graded each peptide strictly on human efficacy evidence for shoulder injury specifically — rotator-cuff, labral or shoulder-tendon repair — not on Achilles, ACL or eye data, and not on mechanism. Evidence tiers were sourced from a 2025 HSS Journal systematic review of BPC-157 in orthopaedic sports medicine, a 2026 thymosin β-4/TB-500 scoping review, the primary rat rotator-cuff and ACL studies, and a 2025 PRP rotator-cuff meta-analysis, cross-checked against FDA and WADA regulatory status. Where the only data are preclinical, the grade is capped at C; anecdotal dosing is flagged Grade D and never treated as evidence.
- Human shoulder evidence. RCT, cohort or case series in rotator-cuff, labral or shoulder-tendon injury specifically. All three peptides currently have none.
- Condition-relevant preclinical dossier. Depth and quality of shoulder- or tendon/ligament-specific animal and in-vitro data, understood as hypothesis-generating only.
- Safety data for shoulder use. Controlled human safety in this indication; product-quality and peri-surgical contamination risk from the research-chemical supply chain.
- Regulatory & sport status. FDA approval/503A status and WADA/DoD prohibition, verified against 2026 official sources.
Rating scale: Ratings reflect strength of evidence for the SHOULDER, not popularity. A high rating requires human efficacy data for rotator-cuff or shoulder injury, which no peptide currently has — so all three cap at 2/5 with a Grade C ceiling.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | BPC-157 (Body Protection Compound-157) | C | 2.0 | Understanding why the peptide is popular for the rotator cuff — and why a single rat abstract does not equal human proof. | Not FDA-approved; no legitimate shoulder indication |
| 2 | TB-500 / Thymosin β-4 | C | 1.5 | Seeing where real thymosin β-4 human data actually sit — and why they don't cover the shoulder. | Not FDA-approved; no legitimate shoulder indication |
| 3 | GHK-Cu (Copper Tripeptide-1) | C | 1.0 | Understanding why a plausible collagen-repair mechanism still fails to translate into durable shoulder benefit. | Not FDA-approved; no legitimate shoulder indication |
BPC-157 (Body Protection Compound-157)
Only peptide with a rotator-cuff study — a single unpublished rat abstract
BPC-157 is a synthetic 15-amino-acid stable gastric pentadecapeptide and the only peptide here with a shoulder-specific study, which is why it tops this comparison — 'best-studied,' not proven. In a rat model, 48 animals underwent detachment of the supraspinatus and infraspinatus tendons and were randomized to BPC-157 (10 µg/kg intraperitoneally) or saline, then assessed at 2, 4, 8 and 12 weeks, with the peptide animals showing reported total functional recovery similar to healthy controls. The critical caveat is that this result is a conference-abstract supplement, not a peer-reviewed full paper, and has never appeared as a published primary article — so it carries low evidentiary weight even within the animal tier. The more robust orthopaedic data are in Achilles models: tendon-to-bone healing of a detached Achilles that did not heal in controls, opposition to corticosteroid-induced impairment, and transected-Achilles healing with higher load-to-failure, stiffness and better collagen organization. Mechanistically it drives angiogenesis via the VEGFR2-Akt-eNOS axis and upregulates the growth-hormone receptor in tendon fibroblasts. But none of this involves a human shoulder. The HSS Journal systematic review found only 1 clinical study among 36 included — not a cuff trial — and the first registered BPC-157 efficacy RCT targets hamstring strain, not the shoulder. For rotator-cuff injury it is Grade C: biologically plausible, clinically unproven.
Strengths
- The only peptide with a shoulder-specific (rat rotator-cuff, supraspinatus/infraspinatus) study, plus the deepest and most internally consistent rodent tendon and tendon-to-bone healing dataset
- Plausible mechanism for a hypovascular enthesis — angiogenesis via VEGFR2-Akt-eNOS, fibroblast migration and growth-hormone-receptor upregulation
- A first controlled human trial (Phase 2 hamstring RCT, NCT07437547) is finally underway, so a real read-out is eventually coming
Weaknesses
- Zero human shoulder evidence — no RCT, cohort or case series; the shoulder datapoint is a single unpublished conference abstract, and only 1 clinical study exists across the entire orthopaedic BPC-157 literature
- Not FDA-approved; sold as a 'research chemical' with real contamination and quality risk, a serious concern around peri-surgical shoulder use
- Prohibited at all times by WADA (S0) and on the DoD prohibited list — an anti-doping violation for tested athletes
- Best for
- Understanding why the peptide is popular for the rotator cuff — and why a single rat abstract does not equal human proof.
- Pricing
- Not FDA-approved; no legitimate shoulder indication
Source: Chang & Sikirić, FASEB J 2014 (rat rotator-cuff, 844.9)
TB-500 / Thymosin β-4
Real human trials — but for the eye, not tendon or shoulder
Thymosin β-4 (Tβ4) is a 43-amino-acid actin-sequestering regenerative protein; TB-500 is the synthetic acetylated heptapeptide fragment (Ac-LKKTETQ) sold for tissue repair, and the two are not the same molecule — human data for one does not transfer to the other. In preclinical work Tβ4 promotes cell migration, angiogenesis, anti-inflammatory chemokine down-regulation and collagen deposition across wound, cardiac and soft-tissue models, and its core action is G-actin sequestration, mobilizing the monomer pool cells use to migrate and close wounds. A 2026 scoping review mapped 80 included studies (of 1,772 screened) and found the field dominated by in-vitro and animal designs, mostly of Tβ4 rather than TB-500, with the most-studied tissues being skin, vascular, ocular and bone — not a single dedicated rotator-cuff model surfaced. For the shoulder the case is therefore mechanism-by-analogy only. Real human RCTs exist, but they belong to full-length Tβ4 ophthalmic solution (RGN-259) for neurotrophic keratopathy and dry eye — and even there results are mixed, with the SEER-1 Phase III primary endpoint not met. That is a different molecule, a topical eye route, and an unrelated indication. There is no human trial of TB-500 or Tβ4 for tendon, rotator-cuff, labral or any shoulder injury. It ranks below BPC-157 because it has no shoulder-specific study at all. For the shoulder it is Grade C, drifting to D where use rests purely on athlete anecdote.
Strengths
- A genuine human safety and efficacy signal for full-length thymosin β-4 (Phase III ophthalmic trials) — more human exposure than most grey-market peptides
- Plausible actin-sequestration mechanism supporting cell migration, angiogenesis and matrix remodeling relevant to soft-tissue repair
- Broad preclinical footprint across wound, cardiac, vascular, ocular and bone models
Weaknesses
- Human trials are for full-length Tβ4 eye drops in dry eye and corneal disease, not the injected TB-500 fragment and not tendon or shoulder — and even those results were mixed
- No shoulder-specific study of any tier; the case for the cuff is mechanism-by-analogy only
- Prohibited at all times by WADA as a growth factor (S2.3), explicitly named, with no Therapeutic Use Exemption — and it carries a theoretical pro-metastatic signal
- Best for
- Seeing where real thymosin β-4 human data actually sit — and why they don't cover the shoulder.
- Pricing
- Not FDA-approved; no legitimate shoulder indication
Source: Thymosin β-4 & TB-500 scoping review, Applied Sciences 2026
GHK-Cu (Copper Tripeptide-1)
One musculoskeletal study — transient benefit, no strength gain
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine:Cu²⁺) whose plasma level falls roughly 60% between ages 20 and 60 — a well-characterized 'matrikine' that modulates thousands of tissue-repair genes, supports collagen and elastin synthesis, and supplies copper as a cofactor for lysyl-oxidase collagen cross-linking. Its regenerative rationale is genuinely appealing, but for the shoulder it is the weakest of the three. The single most relevant musculoskeletal study is in ligament, not tendon: in a rat ACL-reconstruction model, 72 rats received intra-articular saline, 0.3, or 3 mg/mL GHK-Cu weekly for four weeks, and the peptide produced only a transient reduction in knee laxity at 6 weeks that was gone by 12 weeks, with no significant improvement in ultimate load-to-failure or gait — the authors concluded the benefit could not last once treatment was discontinued. This is an unusually honest negative-to-equivocal result and the most informative musculoskeletal datapoint GHK-Cu has. Its genuine human evidence is entirely topical: a positive multicenter RCT in diabetic neuropathic foot ulcers and small cosmetic skin-quality trials. There is no human trial of GHK-Cu for tendon, rotator-cuff or any shoulder injury, and no controlled human data for the injected or systemic route at all. It also carries an absolute contraindication in Wilson's disease and other copper-overload disorders. Grade C for mechanism, effectively D as a shoulder therapy.
Strengths
- Well-characterized matrikine biology — modulates tissue-repair gene expression and supplies copper for lysyl-oxidase collagen cross-linking, a plausible route to organized collagen
- Genuine positive human RCT evidence in a healing indication (diabetic neuropathic foot ulcers, topical) plus cosmetic skin-quality data
- The one controlled musculoskeletal study is unusually honest and transparent about its transient, non-durable result
Weaknesses
- Its single musculoskeletal study (rat ACL, a ligament) showed only transient benefit that vanished after stopping and NO improvement in load-to-failure — the opposite of durable structural repair
- All genuine human evidence is dermatologic/topical; there is no human shoulder trial and no controlled data for the injected/systemic route
- Absolute contraindication in Wilson's disease and other copper-overload disorders, copper allergy, and concurrent copper-chelation therapy; theoretical copper accumulation with chronic dosing
- Best for
- Understanding why a plausible collagen-repair mechanism still fails to translate into durable shoulder benefit.
- Pricing
- Not FDA-approved; no legitimate shoulder indication
Source: Fu et al., J Orthop Res 2015 (rat ACL, doi:10.1002/jor.22831)
Feature comparison
| Feature | BPC-157 (Body Protection Compound-157) | TB-500 / Thymosin β-4 | GHK-Cu (Copper Tripeptide-1) |
|---|---|---|---|
| Human RCT in shoulder injury | — | — | — |
| Shoulder-specific animal study | — | — | — |
| Broader tendon/ligament preclinical data | — | — | — |
| Feature | BPC-157 (Body Protection Compound-157) | TB-500 / Thymosin β-4 | GHK-Cu (Copper Tripeptide-1) |
|---|---|---|---|
| FDA-approved | — | — | — |
| WADA-prohibited (all times) | — | — | — |
| On DoD prohibited list | — | — | — |
Frequently asked
Is there any peptide proven to heal a rotator-cuff tear in humans?
No. As of 2026 there is no human randomized controlled trial showing any peptide heals rotator-cuff, labral, or shoulder-tendon injury. A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 544 records and included 36 studies — 35 preclinical and exactly 1 clinical, and that single clinical study was not a rotator-cuff trial. A 2026 scoping review of thymosin β-4 and TB-500 included 80 studies and found the field weighted toward mixed and in-vitro designs, again with no rotator-cuff human trial. Every efficacy claim for the shoulder therefore rests on animal and cell-culture data. All three peptides here are graded C — preclinical only — biologically plausible but clinically unproven for shoulder injury.
Which peptide has the most shoulder-relevant evidence?
BPC-157 — it is the only one with a shoulder-specific study. In a rat model, 48 animals underwent detachment of the supraspinatus and infraspinatus tendons and were randomized to BPC-157 (10 µg/kg intraperitoneally) or saline, with reported full functional recovery, plus a consistent rodent tendon and tendon-to-bone healing base. But that rat rotator-cuff result is an unpublished conference-abstract supplement, not a peer-reviewed full paper, so it carries low evidentiary weight even within the animal tier. There is no human shoulder evidence of any kind. BPC-157 therefore remains Grade C — the strongest condition-relevant preclinical signal of the three, but still far short of human proof.
Can I use BPC-157 or TB-500 around shoulder surgery to recover faster?
There is no controlled human evidence that doing so improves cuff-repair outcomes, and there are real reasons for caution. The peptides are sold as unregulated research chemicals whose vials have tested positive for endotoxins, heavy metals and inaccurate dosing — a meaningful infection and contamination concern around any surgical site. Both BPC-157 and TB-500 also carry a theoretical pro-angiogenic and, for TB-500, pro-metastatic signal, a serious caution for anyone with a cancer history. And for any tested athlete or military service member, use is an automatic doping violation. This is a conversation for your orthopaedic surgeon, not a supplement vendor.
Is GHK-Cu good for tendons and ligaments?
The mechanism — collagen synthesis and copper-dependent lysyl-oxidase cross-linking — is plausible, but the evidence is weak for musculoskeletal use. The single most relevant study is in ligament, not tendon: in a rat ACL-reconstruction model, GHK-Cu produced a transient reduction in knee laxity at 6 weeks that was gone by 12 weeks, with no significant improvement in ultimate load-to-failure or gait; the authors concluded the benefit could not last once treatment stopped. GHK-Cu's genuine human evidence is topical and dermatologic — diabetic ulcer and skin-quality trials — not the shoulder. For a torn cuff it is the weakest of the three: Grade C for mechanism, effectively D as a shoulder therapy.
What actually has human evidence for rotator-cuff problems?
The evidence-based standard of care — structured physical therapy, load management, and, for appropriate tears, surgical repair — has the strongest human support. Among injectable regenerative add-ons, platelet-rich plasma (PRP) is the only one with a meaningful, if still debated, human trial base for rotator-cuff disease; peptides are not yet at that level. A full-thickness cuff tear is a structural injury, and animal collagen-organization data do not establish that an injected peptide re-approximates a retracted, torn human tendon to bone. From a functional standpoint the durable path is rebuilding tissue capacity and load tolerance under clinician guidance, not an unproven injectable.